

STIC-EIC1600/2900

280756

From: SHOBHA KANTAMNENI [shobha.kantamneni@uspio.gov]  
 Sent: Monday, December 15, 2008 8:54 PM  
 To: STIC-EIC1600/2900  
 Subject: Search Request, Case/Application No.: 10/652745

P  
 Hp



ACFDB72.pdf

Requester: SHOBHA KANTAMNENI (P/1617)  
 Art Unit: GROUP ART UNIT 1617  
 Employee Number:  
 Office Location: REM 4A5  
 Phone Number: (571)272-2930

Case/Application number: 10/652745  
 Priority Filing Date:  
 Format For Search Results: No selection  
 Meaning of unusual acronyms or initialisms:

Identify the novelty:

Additional comments:

Please, do structure search for compounds of formula (I) as in claim 75. If too many hits, limit to antimicrobial activity of these compounds.

Attachment: Yes (ACFDB72.pdf)

\*\*\*\*\*  
 Searcher:.....  
 Searcher Phone:.....  
 Date Searcher picked up:.....  
 Date completed:.....  
 Searcher Prep Time:.....  
 Online time:.....

\*\*\*\*\*  
 Type of Search.....  
 SN #:.....  
 S/L:.....  
 Incode/Transl:.....  
 Structure #:.....  
 Inventor:.....  
 Litigation:.....

\*\*\*\*\*  
 Vendors/Coat where applicable.....  
 STIC.....  
 DTALOG.....  
 QUESTEL/ORBIT.....  
 LEXIS/NEXIS.....  
 SEQUENCE SYSTEM.....  
 DNA/INVENT.....  
 OTHER (Specify):.....

=&gt; d ibib abs hitstr l19 1

L19 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:203593 HCAPLUS Full-text  
 DOCUMENT NUMBER: 140:234733  
 TITLE: Carboxylic acid microbicides for food, feed and water  
 INVENTOR(S): Schasteen, Charles S.; Wu, Jennifer  
 ; Buttin, Pierre; Hillebrand, Pieter  
 ; Scott, Fredrick F.; Vasquez-Anon,  
 Mercedes  
 PATENT ASSIGNEE(S): Novus International, LLP, USA; Novus International,  
 Inc.  
 SOURCE: PCT Int. Appl., 146 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019683	A2	20040311	WO 2003-US27323	20030829
WO 2004019683	A3	20040415		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, LC, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003268342	A1	20040319	AU 2003-268342	20030829
EP 1531672	A2	20050525	EP 2003-749300	20030829
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003013917	A	20050705	BR 2003-13917	20030829
IN 2005CN00275	A	20070330	IN 2005-CN275	20050225
MX 2005PA02307	A	20051018	MX 2005-PA2307	20050228
PRIORITY APPLN. INFO.:			US 2002-407050P	P 20020830
			US 2003-441384P	P 20030121
			US 2003-441584P	P 20030121
			US 2003-456673P	P 20030321
			US 2003-456732P	P 20030321
			US 2003-465549P	P 20030425
			WO 2003-US27323	W 20030829

OTHER SOURCE(S): MARPAT 140:234733  
 AB Antimicrobial compns. and combinations for food, feed and water comprise carboxylic acids, preferably Alimet.  
 IT 50-21-5, Lactic acid, biological studies 64-16-6, Formic acid, biological studies 64-19-7, Acetic acid, biological studies 55-85-0, Benzoic acid, biological studies 77-92-9, Citric acid, biological studies 79-03-4, Propionic acid, biological studies 79-14-1, Glycolic acid, biological studies 87-69-4, Tartaric acid, biological studies 90-64-2, Mandelic acid 107-92-6, Butyric acid, biological studies 110-15-6, Succinic acid, biological studies 110-17-6, Fumaric acid, biological studies 110-44-1,

Sorbic acid 110-94-1, Glutaric acid 124-04-9, Adipic acid, biological studies 583-91-5, Alimet 6915-15-7, Malic acid 10643-35-3, Boric acid, biological studies 566823-60-5, Alimet-lactic acid mixture 566823-61-6, Alimet-formic acid mixture 566823-62-7, Alimet-citric acid mixture 566823-63-3, Alimet-butyric acid mixture 566823-64-9, Alimet-propionic acid mixture 566823-65-0, Formic acid-lactic acid mixture 566823-66-1, Butyric acid-lactic acid mixture 566823-67-2 566823-68-3 566823-69-4, Alimet-fumaric acid mixture 566823-70-7, Alimet-tartaric acid mixture 566823-71-8, Alimet-sorbic acid mixture 566823-72-9, Alimet-malic acid mixture  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (carboxylic acid microbicides for food, feed and water)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 64-18-6 HCAPLUS

CN Formic acid (CA INDEX NAME)



RN 64-19-7 HCAPLUS

CN Acetic acid (CA INDEX NAME)




RN 65-85-0 HCAPLUS

CN Benzoic acid (CA INDEX NAME)




RN 77-92-9 HCAPLUS


CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (CA INDEX NAME)



RN 79-09-4 HCAPLUS  
CN Propanoic acid (CA INDEX NAME)




RN 79-14-1 HCAPLUS  
CN Acetic acid, 2-hydroxy- (CA INDEX NAME)



RN 87-69-4 HCAPLUS  
CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 90-64-2 HCAPLUS  
CN Benzeneacetic acid,  $\alpha$ -hydroxy- (CA INDEX NAME)



RN 107-92-6 HCAPLUS  
CN Butanoic acid (CA INDEX NAME)




RN 110-15-6 HCAPLUS  
CN Butanedioic acid (CA INDEX NAME)




RN 110-17-8 HCAPLUS  
CN 2-Butenedioic acid (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 110-44-1 HCAPLUS  
CN 2,4-Hexadienoic acid, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 110-94-1 HCAPLUS  
CN Pentanedioic acid (CA INDEX NAME)




RN 124-04-9 HCAPLUS  
CN Hexanedioic acid (CA INDEX NAME)



RN 583-91-5 HCAPLUS  
CN Butanoic acid, 2-hydroxy-4-(methylthio)- (CA INDEX NAME)



RN 6915-15-7 HCAPLUS  
CN Butanedioic acid, 2-hydroxy- (CA INDEX NAME)




RN 10043-35-3 HCAPLUS  
 CN Boric acid (H3BO3) (CA INDEX NAME)



RN 666823-60-5 HCAPLUS  
 CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with 2-hydroxypropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5  
 CMF C5 H10 O3 S



CM 2


CRN 50-21-5  
 CMF C3 H6 O3



RN 666823-61-6 HCAPLUS  
 CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with formic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5  
 CMF C5 H10 O3 S



CM 2


CRN 64-18-6  
 CMF C H2 O2



RN 666823-62-7 HCAPLUS  
 CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with  
 2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)


CM 1

CRN 583-91-5  
 CMF C5 H10 O3 S



CM 2


CRN 77-92-9  
 CMF C6 H8 O7



RN 666823-63-8 HCAPLUS  
 CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with butanoic acid (9CI)  
 (CA INDEX NAME)

CM 1

CRN 583-91-5  
 CMF C5 H10 O3 S



CM 2


CRN 107-92-6  
 CMF C4 H8 O2



RN 666823-64-9 HCAPLUS  
 CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with propanoic acid (9CI)  
 (CA INDEX NAME)

CM 1

CRN 583-91-5  
 CMF C5 H10 O3 S



CM 2

CRN 79-09-4  
 CMF C3 H6 O2



RN 666823-65-0 HCAPLUS  
 CN Propanoic acid, 2-hydroxy-, mixt. with formic acid (9CI) (CA INDEX NAME)

CM 1

CRN 64-18-6  
 CMF C H2 O2



CM 2

CRN 50-21-5  
 CMF C3 H6 O3




RN 666823-66-1 HCAPLUS  
 CN Butanoic acid, mixt. with 2-hydroxypropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 107-92-6



CMF C4 H8 O2




CM 2

 CRN 50-21-5  
 CMF C3 H6 O3


RN 666823-67-2 HCAPLUS

 CN Butanoic acid, mixt. with formic acid and 2-hydroxypropanoic acid (9CI)  
 (CA INDEX NAME)

CM 1

 CRN 107-92-6  
 CMF C4 H8 O2


CM 2

 CRN 64-18-6  
 CMF C H2 O2


CM 3

 CRN 50-21-5  
 CMF C3 H6 O3



RN 666823-68-3 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with butanoic acid, formic acid and 2-hydroxypropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5


CMF C5 H10 O3 S



CM 2

CRN 107-92-6

CMF C4 H8 O2



CM 3

CRN 64-18-6

CMF C H2 O2



CM 4

CRN 50-21-5

CMF C3 H6 O3




RN 666823-69-4 HCAPLUS

CN 2-Butenedioic acid (2E)-, mixt. with 2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5

CMF C5 H10 O3 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 666823-70-7 HCAPLUS

CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, mixt. with  
2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5

CMF C5 H10 O3 S




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 666823-71-8 HCAPLUS

CN 2,4-Hexadienoic acid, (2E,4E)-, mixt. with  
2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5

CMF C5 H10 O3 S




CM 2

CRN 110-44-1

CMF C6 H8 O2

Double bond geometry as shown.




RN 666823-72-9 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with hydroxybutanedioic acid (9CI) (CA INDEX NAME)

CM 1

CRN 6915-15-7


CMF C4 H6 O5



CM 2

CRN 583-91-5

CMF C5 H10 O3 S



Please note: The results from L8 have been saved, should additional citations be required.

=> d que stat l10  
L3 STR



REP G1=(0-2) CH2  
VAR G2=OH/NH2/10/12  
NODE ATTRIBUTES:  
DEFAULT MLEVEL IS ATOM  
DEFAULT ECLEVEL IS LIMITED  
ECOUNT IS M1-X4 C AT 1

GRAPH ATTRIBUTES:  
RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 14

STEREO ATTRIBUTES: NONE

L5 31381 SEA FILE=REGISTRY SSS FUL L3  
L6 86246 SEA FILE=HCAPLUS ABB=ON L5  
L7 558 SEA FILE=HCAPLUS ABB=ON L6 AND ?ANTIMICROB?  
L8 117 SEA FILE=HCAPLUS ABB=ON L7 AND (FOOD OR WATER)  
L9 6 SEA FILE=REGISTRY ABB=ON (FORMIC ACID OR BUTYRIC ACID OR FUMARIC ACID OR LACTIC ACID OR BENZOIC ACID OR PROPIONIC ACID)/CN  
L10 28 SEA FILE=HCAPLUS ABB=ON L8 AND (L9 OR FORMIC ACID OR BUTYRIC ACID OR FUMARIC ACID OR LACTIC ACID OR BENZOIC ACID OR PROPIONIC ACID)

=> d ibib abs hitstr l10 1-28

L10 ANSWER 1 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:1177642 HCAPLUS Full-text  
DOCUMENT NUMBER: 147:474695  
TITLE: Topical therapeutic delivery system  
INVENTOR(S): Murad, Howard; Akyuz, Rafael  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 35pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007117352	A2	20071018	WO 2007-US3427	20070208
WO 2007117352	A3	20080110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,

KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, ME, MG,  
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,  
 RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,  
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-771016P P 20060208

OTHER SOURCE(S): MARPAT 147:474695

AB An oil-in-water emulsion topical delivery system comprising (i) an oil phase;  
 (ii) an aqueous phase; (iii) phenoxyethanol at a concentration of from about  
 2.0% to about 2.7% based on the total weight of the composition; (iv) an  
 effective exfoliating amount of a hydrophobic hydroxycarboxylic acid selected  
 from the group consisting of orthohydroxybenzoic acid, hydroxycarboxylic acids  
 containing a C12-C24 fatty acid esterified to the alpha carbon hydroxyl  
 group, and hydroxycarboxylic acids containing a C12-C24 fatty alc. esterified  
 to a carboxyl group; (v) a non-ionic emulsifier having an HLB of from about 7  
 to about 10; and (vi) at least one skin-supporting or dermatopharmacologically  
 active agent.

IT 50-21-5, 2-Hydroxypropanoic acid, biological studies  
 RL: COS (Cosmetic use); MOA (Modifier or additive use); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (topical therapeutic delivery system)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)




IT 63-68-3, Methionine, biological studies  
 RL: COS (Cosmetic use); PAC (Pharmacological activity); THU (Therapeutic  
 use); BIOL (Biological study); USES (Uses)  
 (topical therapeutic delivery system)

RN 63-68-3 HCAPLUS

CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



IT 79-09-4D, Propionic acid, derivs.  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (topical therapeutic delivery system)

RN 79-09-4 HCAPLUS

CN Propanoic acid (CA INDEX NAME)



L10 ANSWER 2 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1029691 HCAPLUS Full-text  
 DOCUMENT NUMBER: 147:330488  
 TITLE: Topical product for growth stimulation of  
 Propionibacteria and its use for treating skin  
 diseases  
 INVENTOR(S): Sauermann, Gerhard; Sauermann, Christian  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: Ger. Offen., 6pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102006010720	A1	20070913	DE 2006-102006010720	20060308
PRIORITY APPLN. INFO.:			DE 2006-102006010720	20060308

AB The invention concerns a topical formulation for the stimulation of the symbiotic growth of Propionibacteria on skin, mucosa and sebaceous glands; the compns. contain at least one precursor for vitamins produced by Propionibacteria and/or antimicrobial agents, fungicides, sugars, iron salts and iron complexes. Typical precursors are betaine, dimethylbenzimidazole, flavins, mixts. of L-amino acids and propionic acid, and lactose. Diaper rash, seborrhea, mycosis and acne can be treated with the compns. Thus a W/O emulsion contained (weight/weight%): emulsifier 2; oil 10; trimethylglycine 3; flavin 1; 5,6-dimethylbenzimidazole 0.5; methionine 0.5; iron-porphyrin complex 3; amino acids 1; lactose 1; water to 100.

IT 63-68-3, L-Methionine, biological studies  
 RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)  
 (topical product for growth stimulation of Propionibacteria and its use for treating skin diseases)

RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:912145 HCAPLUS Full-text  
 DOCUMENT NUMBER: 147:263392  
 TITLE: Fragranced therapeutic delivery system comprising  
 phenoxyethanol and exfoliating hydroxycarboxylic acids  
 INVENTOR(S): Murad, Howard; Akyuz, Rafael  
 PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 43pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007092085	A2	20070816	WO 2006-US48383	20061220
WO 2007092085	A3	20080221		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2005-751635P P 20051220

AB The present invention relates to multifunctional topical delivery systems for providing long-lasting delivery of fragrance as. well as skin-supporting and/or pharmaceutically active ingredients comprising (i) an oil phase, (ii) an aqueous phase, (iii) phenoxyethanol at a concentration of about 2.0% to about 2.7% based on the total weight of the composition, (iv) an effective exfoliating amount of a hydrophobic hydroxycarboxylic acid selected from the group consisting of o-hydroxybenzoic acid, hydroxycarboxylic acids containing a C12-24 fatty acid esterified to the alpha carbon hydroxyl group, hydroxycarboxylic acids containing a C12-24 fatty alc. esterified to a carboxyl group, (v) a nonionic emulsifier having an HLB of about 7 to about 10, (vi) a fragrance composition, and (vii) at least one skin-supporting or dermatopharmaceutically active agent. Thus, an extended fragrance delivery vehicle contained water 69.14, Pemulen TR-1 0.18, Dissolvine 220 0.05, aminomethylpropanol 0.90, phenoxyethanol 2.70, salicylic acid 0.50, Hetester PHA 2.00, Beantree 2.00, Bernel Ester CO 1.00, Simulsol 165 0.01, mango butter 0.01, olive butter, vitamin E acetate, SD Alc. 40-B 20.00, and essential oil blend 0.50 parts, resp.

IT 50-21-5, 2-Hydroxypropanoic acid, biological studies  
 63-68-3, Methionine, biological studies 79-09-4D,  
 Propionic acid, derivs.

RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study);  
 USES (Uses)

(fragranced topical therapeutic delivery system comprising  
 phenoxyethanol and exfoliating hydroxycarboxylic acids)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)




RN 63-68-3 HCAPLUS


CN L-Methionine (CA INDEX NAME)



Absolute stereochemistry.



RN 79-09-4 HCAPLUS  
 CN Propanoic acid (CA INDEX NAME)



L10 ANSWER 4 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:512453 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 146:481109  
 TITLE: Composition comprising a bacteriocin and an extract  
 from a plant of the Labiatae family  
 INVENTOR(S): Coyne, Bob; Faragher, John; Gouin, Sebastien; Hansen,  
 Carsten Bjorn; Ingram, Richard; Isak, Torben; Thomas,  
 Linda Valerie; Tse, Kathryn Louise  
 PATENT ASSIGNEE(S): Danisco A/S, Den.  
 SOURCE: U.S. Pat. Appl. Publ., 31pp., Cont.-in-part of U.S.  
 Ser. No. 820,147.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070104809	A1	20070510	US 2006-568324	20061013
GB 2388581	A	20031119	GB 2003-19817	20030822
US 20050042341	A1	20050224	US 2004-820147	20040408
WO 2005018333	A1	20050303	WO 2004-GB3423	20040806
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,				
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,				
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,				
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,				
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,				
SN, TD, TG				

PRIORITY APPLN. INFO.: GB 2003-19817 A 20030822  
 US 2003-497409P P 20030822  
 GB 2003-23335 A 20031006  
 US 2003-533053P P 20031230  
 US 2004-560270P P 20040408  
 US 2004-820147 A2 20040408  
 WO 2004-GB3423 W 20040806


AB A composition comprises (a) an antimicrobial material; and (b) an extract obtained from or obtainable from a plant of the Labiatae family, wherein (a) and (b) are different; wherein the composition contains phenolic diterpenes in an amount of greater than 1.0 weight %, based on the composition, and wherein when the antimicrobial material consists of nisin, the composition comprises carvacrol in an amount of less than 0.075 weight % based on the composition and carvone in an amount of less than 15 weight % based on the composition. Thus, a composition comprised nisin and exts. of *Rosmarinus officinalis* containing >3.5% phenolic diterpenes, increasing nisin kill and growth control of Gram-neg. bacteria in food models. The results demonstrated that the phenolic diterpenes, carnosic acid and carvacrol and rosmarinic acid were implicated in the antimicrobial activity.

IT 922-55-4  
 RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (antimicrobial composition comprising bacteriocin and extract from  
 plant of Labiatae family)

RN 922-55-4 HCAPLUS

CN L-Cysteine, S-[(2R)-2-amino-2-carboxyethyl]- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 5 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:384806 HCAPLUS Full-text

DOCUMENT NUMBER: 146:365085

TITLE: Phenylthienylmethylthiazolidine-2,4-dione for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof

INVENTOR(S): Boulle, Christophe; Dalko, Maria

PATENT ASSIGNEE(S): L'Oreal, Fr.

SOURCE: U.S. Pat. Appl. Publ., 29pp.  
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070078175	A1	20070405	US 2006-543193	20061005
FR 2891543	A1	20070406	FR 2005-53017	20051005
EP 1775294	A1	20070418	EP 2006-120810	20060918
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
JP 2007126451	A	20070524	JP 2006-273313	20061004
PRIORITY APPLN. INFO.:				
			FR 2005-53017	A 20051005
			US 2005-726207P	P 20051014

OTHER SOURCE(S): MARPAT 146:365085

AB The present invention relates to novel phenylfurylmethylthiazolidine-2,4-dione and phenylthienylmethylthiazolidine-2,4-dione compds. and administration thereof for stimulating or inducing the growth of keratinous fibers and/or slowing down their loss and/or increasing their d. and/or improving their appearance. Thus, hair lotion was prepared containing 4-[5-[(2,4-Dioxo-1,3-

thiazolidin-5-yl)methyl]-2-furyl]benzoic acid 1.0 g, propylene glycol 30.0 g, Et alc. 40.0 g and water to 100 g.

IT 63-68-3, Methionine, biological studies


RL: COS (Cosmetic use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phenylthienylmethylthiazolidine-2,4-dione compds. for stimulating or inducing the growth of keratinous fibers and/or slowing loss thereof)

RN 63-68-3 HCAPLUS

CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:258206 HCAPLUS Full-text

DOCUMENT NUMBER: 146:323686

TITLE: In-can and dry coating antimicrobial compositions having hydroxy analogs of methionine for paints

INVENTOR(S): Abou-Nemeh, Ibrahim

PATENT ASSIGNEE(S): Novus International Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 21pp.  
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070053866	A1	20070308	US 2006-469967	20060905
PRIORITY APPLN. INFO.:			US 2005-714387P	P 20050906
OTHER SOURCE(S):	MARPAT 146:323686			

AB The invention provides coating compns. that comprise antimicrobial agent comprising at least one hydroxy analog of methionine and a binder. The antimicrobial agents may be used as preservatives to inhibit a broad spectrum of microorganisms in the coating compns. For example, paint preservatives contained BIOX-ASL, which composes of 2-hydroxy 4-methylthio butanoic acid, formic acid, phosphoric acid and lactic acid.

IT 59-21-5, Lactic acid, biological studies

63-66-3D, Methionine, analogs 64-18-6, Formic acid, biological studies 583-91-5, Biox A

583-91-5D, 2-Hydroxy-4-methylthio-butanoic acid, metal chelates

928642-04-G, Biox-ASL 928642-05-1, Biox-AWD

928642-06-2

RL: BSU (Biological study, unclassified); TEM (Technical or engineered material use); BIOL (Biological study); USES (Uses)

(in-can and dry coating antimicrobial compns. having hydroxy analogs of methionine for paints)


RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 63-68-3 HCAPLUS  
CN L-Methionine (CA INDEX NAME)


Absolute stereochemistry.




RN 64-18-6 HCAPLUS  
CN Formic acid (CA INDEX NAME)



RN 583-91-5 HCAPLUS  
CN Butanoic acid, 2-hydroxy-4-(methylthio)- (CA INDEX NAME)



RN 583-91-5 HCAPLUS  
CN Butanoic acid, 2-hydroxy-4-(methylthio)- (CA INDEX NAME)



RN 928642-04-0 HCAPLUS  
CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with formic acid, 2-hydroxypropanoic acid and phosphoric acid (CA INDEX NAME)

CM 1


CRN 7664-38-2  
CMF H3 O4 P



CM 2

CRN 583-91-5

CMF C5 H10 O3 S



CM 3

CRN 64-18-6

CMF C H2 O2



CM 4

CRN 50-21-5

CMF C3 H6 O3




RN 928642-05-1 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with formic acid and propanoic acid (CA INDEX NAME)

CM 1

CRN 583-91-5


CMF C5 H10 O3 S



CM 2

CRN 79-09-4

CMF C3 H6 O2



CM 3

CRN 64-18-6

CMF C H2 O2




RN 928642-06-2 HCAPLUS

CN 2-Butenedioic acid (2E)-, mixt. with benzoic acid and  
 2-hydroxy-4-(methylthio)butanoic acid calcium salt (2:1) (CA INDEX NAME)

CM 1

CRN 4857-44-7

CMF C5 H10 O3 S . 1/2 Ca




● 1/2 Ca

CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



CM 3


CRN 65-85-0

CMF C7 H6 O2



L10 ANSWER 7 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:204728 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 147:230343  
 TITLE: Isolation and partial characterization of a novel bacteriocin produced by *Lactococcus lactis* ssp. *lactis* MC38  
 AUTHOR(S): Tukul, Caglia; Avsaroglu, M. Dilek; Simsek, Omer; Akcelik, Mustafa  
 CORPORATE SOURCE: Department of Medical Microbiology and Immunology School of Medicine, University of California at Davis, Davis, CA, USA  
 SOURCE: Journal of Food Safety (2007), 27(1), 17-29  
 CODEN: JFSADP; ISSN: 0149-6085  
 PUBLISHER: Blackwell Publishing, Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB This work presents the isolation and partial characterization of a new lactococcal bacteriocin produced by *Lactococcus lactis* ssp. *lactis* MC38. The bacteriocin demonstrated broad spectrum of inhibition activity against both pathogenic and food spoilage organisms, and various lactic acid bacteria. This antimicrobial substance appeared to be proteinaceous because its activity was completely inactivated by proteinase K and  $\alpha$ -chymotrypsin. It was heat and pH stable. The apparent mol. mass of the purified bacteriocin, determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, was 8.0 kDa. The amino acid composition of the studied bacteriocin was found to be quite different from known lactococcal bacteriocins. The calcn. of the number of amino acid residues in the bacteriocin mol. revealed that it contained 62 amino acids.  
 IT 63-68-3, Methionine, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study) (isolation and partial characterization of a bacteriocin produced by *Lactococcus lactis* ssp. *lactis*)  
 RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 8 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2006:1342373 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 146:77532  
 TITLE: Methods and kits for obtaining a metabolic profile of living animal or plant cells in a multi-test format  
 INVENTOR(S): Bochner, Barry; Wiater, Larry  
 PATENT ASSIGNEE(S): Biolog Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 67pp., Cont.-in-part of U.S. Ser. No. 192,161.  
 CODEN: USXXCO

DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060286627	A1	20061221	US 2006-418804	20060505
US 20030162164	A1	20030828	US 2002-126345	20020419
WO 2003089652	A2	20031030	WO 2003-US11866	20030416
WO 2003089652	A3	20040318		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003223660	A1	20031103	AU 2003-223660	20030416
EP 1501938	A2	20050202	EP 2003-719801	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 20050260558	A1	20051124	US 2005-192161	20050727
PRIORITY APPLN. INFO.:				
			US 2001-285541P	P 20010420
			US 2002-126345	B1 20020419
			US 2005-678566P	P 20050505
			US 2005-192161	A2 20050727
			WO 2003-US11866	W 20030416
AB	The present invention relates to growing and testing eukaryotic cells (e.g., animal or plant cells) in a multi-test format. In particular, the present invention provides methods and kits for obtaining a complex metabolic profile of animal cells. In addition, the present invention provides tools for assaying the effects of candidate compounds (e.g., hormones) on substrate utilization by mammalian cells. A549 cells were suspended at 400,000 cells/mL in RPMI salts+RPMI-vitamins+1% Pen/Strep (Penicillin/Streptomycin) without amino acids but containing either 5 % or 20 % dialyzed or non-dialyzed FCS. Cells were dispensed in 50 uL to wells containing a plurality of testing substrates (glycogen, glucose and pyruvate among others) at final concns. of 20, 15, 10.5, 2.5 and 1.2 mM of each testing substrate. The cells were incubated for 2 days at 37° under 5 % CO2-95 % air (preincubation phase), before a redox dye mix was added. The cells were incubated for an addnl. 5 h at 37° under 5 % CO2-95 % air (incubation phase), before color development was measured. A metabolic profile of A549 cells in the presence of serum was obtained.			
IT	50-21-b, Lactic acid, biological studies 56-88-2, Cystathionine 63-68-3, L-Methionine, biological studies 64-18-6, Formic acid, biological studies 67-21-a, DL-Ethionine 79-09-a, Propionic acid, biological studies 107-92-6, Butyric acid, biological studies 110-17-8, Fumaric acid, biological studies 498-59-9, L-Djenkolic acid 1115-47-5, N-Acetyl-DL-methionine 3183-08-2 3226-65-1, L-Methionine sulfoxide 7314-32-1, L-Methionine sulfone RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses) (as testing substrate; kits and methods for obtaining metabolic			



10/652,745

profiles of living animal or plant cells)

RN 50-21-5 HCAPLUS


CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 56-88-2 HCAPLUS

CN L-Homocysteine, S-[(2R)-2-amino-2-carboxyethyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 63-68-3 HCAPLUS

CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.




RN 64-18-6 HCAPLUS

CN Formic acid (CA INDEX NAME)



RN 67-21-0 HCAPLUS

CN Homocysteine, S-ethyl- (CA INDEX NAME)




RN 79-09-4 HCAPLUS

CN Propanoic acid (CA INDEX NAME)




RN 107-92-6 HCAPLUS  
 CN Butanoic acid (CA INDEX NAME)




RN 110-17-8 HCAPLUS  
 CN 2-Butenedioic acid (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 498-59-9 HCAPLUS  
 CN L-Cysteine, S,S'-methylenebis- (CA INDEX NAME)

Absolute stereochemistry.




RN 1115-47-5 HCAPLUS  
 CN Methionine, N-acetyl- (CA INDEX NAME)




RN 3183-08-2 HCAPLUS  
 CN D-Cysteine, S-[(2S)-2-amino-2-carboxyethyl]-, rel- (CA INDEX NAME)

Relative stereochemistry.



RN 3226-65-1 HCAPLUS  
 CN Butanoic acid, 2-amino-4-(methylsulfinyl)-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 7314-32-1 HCAPLUS

CN Butanoic acid, 2-amino-4-(methylsulfonyl)-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 554-94-9 1187-84-4, S-Methyl-L-cysteine

1999-34-4 2488-11-1 3227-09-6

7349-78-2 14486-05-6, Ala-Met 14486-09-0

15080-84-9 36077-33-1 42384-14-5

45243-23-0 90729-28-5 97729-52-7


RL: BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); USES (Uses)

(as testing substrate; kits and methods for obtaining metabolic profiles of living animal or plant cells)

RN 554-94-9 HCAPLUS

CN L-Methionine, glycyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1187-84-4 HCAPLUS


CN L-Cysteine, S-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 1999-34-4 HCAPLUS

CN Methionine, glycyl- (CA INDEX NAME)




RN 2488-11-1 HCAPLUS  
 CN L-Methionine, L-histidyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 3227-09-6 HCAPLUS  
 CN L-Methionine, L-seryl- (CA INDEX NAME)

Absolute stereochemistry.




RN 7349-78-2 HCAPLUS  
 CN L-Methionine, L-methionyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 14486-05-6 HCAPLUS  
 CN L-Methionine, L-alanyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 14486-09-0 HCAPLUS  
 CN L-Methionine, L-valyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 15080-84-9 HCAPLUS  
 CN L-Methionine, L-phenylalanyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 36077-39-1 HCAPLUS  
 CN L-Methionine, L-leucyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 42384-14-5 HCAPLUS  
 CN L-Methionine, L-isoleucyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 45243-23-0 HCAPLUS  
CN L-Methionine, L-arginyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 90729-28-5 HCAPLUS  
CN L-Methionine, L-threonyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 97729-52-7 HCAPLUS  
CN L-Methionine, L-lysyl- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 9 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2006:1076805 HCAPLUS [Full-text](#)  
DOCUMENT NUMBER: 145:363648  
TITLE: Composition containing L-(+)-lactic acid of natural origin  
INVENTOR(S): Pelluz Garcia, Jose Luis  
PATENT ASSIGNEE(S): Dieter De Shart, S.L., Spain  
SOURCE: Span., 7pp.  
CODEN: SPXXAD  
DOCUMENT TYPE: Patent  
LANGUAGE: Spanish  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
ES 2246691	A1	20060216	ES 2004-771	20040330
ES 2246691	B1	20070401		


PRIORITY APPLN. INFO.: ES 2004-771 20040330

AB A PADS composition with application in veterinary, cosmetic, food, or other areas contains 80-95% (weight/weight) L-(+)-lactic acid solution (1.5-6%); 4-12% minerals (Na, K, Cl, Ca, Mg, P); 0.1-0.5% fat; and 0.01-0.05% proteins or peptides. Thus, the antimicrobial PADS composition may be used in wound dressings for horses or dogs and to control or prevent mastitis in dairy cattle.

IT 63-68-3, L-Methionine, biological studies  
 RL: COS (Cosmetic use); FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (lactic acid-containing composition with application in veterinary, cosmetic, food, or other areas)

RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 10 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1039647 HCAPLUS Full-text

DOCUMENT NUMBER: 146:378633

TITLE: Chemical components and antimicrobial effects of Corni fructus

AUTHOR(S): Lee, Soon Ok; Han, Sag-Myung; Kim, Hye-Mi; Jeung, Seung-Kyoung; Choi, Jin-Young; Kang, Il-Jun

CORPORATE SOURCE: Hotel Cuisine, Korea Tourism College, Icheon, 467-745, S. Korea

SOURCE: Han'guk Sikp'um Yongyang Kwahak Hoechi (2006), 35(7), 891-896

CODEN: HSYHFB; ISSN: 1226-3311

PUBLISHER: Korean Society of Food Science and Nutrition

DOCUMENT TYPE: Journal


LANGUAGE: Korean

AB The chemical components and antimicrobial effects were investigated to provide basic data that will predict the usefulness of Corni fructus as food materials. The carbohydrate, crude protein, lipid and ash contents of Corni fructus were 87.7, 3.2, 4.5 and 4.6% in dry basis, resp. Total amino acid content of Corni fructus was 2,470 mg%. Major amino acids of Corni fructus were aspartic acid (523 mg%) and glutamic acid (347 mg%). The compns. of total saturated and unsatd. fatty acids of Corni fructus were 30.8% and 69.2%, resp. Major fatty acids of Corni fructus were linoleic acid (33.3%), palmitic acid (25.1%), linolenic acid (21.6%) and oleic acid (13.2%). The mineral contents of Corni fructus were 2067.5 mg% of K, 372.9 mg% of Ca and 98.4 mg% of Mg in dry basis. The organic acid contents of Corni fructus were 19,478 mg% of formic acid, 18,167 mg% of succinic acid, 14,487 mg% of malonic acid and 13,018 mg% of malic acid. Naengmyon yuksu (beef stock for cold noodles) were prepared with the addition of Corni fructus. Corni fructus added to Naengmyon yuksu inactivated microorganism and inhibited the growth of

microorganism during storage at 10°. Naengmyon yuksu added 1.5 g of Corni fructus showed the highest sensory scores.

IT 63-68-3, L-Methionine, biological studies  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (chemical components and antimicrobial effects of Corni fructus)  
 RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 11 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:606158 HCAPLUS Full-text

DOCUMENT NUMBER: 145:130749

TITLE: Ophthalmic preparation containing tetrandrine and use thereof in treating ophthalmic diseases

INVENTOR(S): Hu, Shixing; Xu, Yangui

PATENT ASSIGNEE(S): Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 25 pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1785192	A	20060614	CN 2004-10093862	20041208
			CN 2004-10093862	20041208

PRIORITY APPLN. INFO.:


AB The ophthalmic preps. (eyedrop, ointment) is composed of tetrandrine 0.001-2, synergistic drugs 0-5, excipient 93-99.999, metal ion complexing agent (disodium edetate) 0-5, isotonic regulator (sodium chloride) 0-10%, solubilizer (0.1-2 M HCl) 0.05-50 mL, thickening agent (hydroxymethyl cellulose) 0-5, cuticle lytic agent (borneol) 0-5, and antioxidant (sodium pyrosulfite) 0-5%, resp. Excipient in eyedrop is injection water; excipient in ointment is wool grease 0-20, paraffin oils 0-20, sodium Et cellulose 0.1-10, and addnl. vaseline to 1000 g. The synergistic drug is antimicrobial, such as erythrocine, kanamycin, gentamicin, amikacin, tobramycin, sisomicin, netilmicin, micromycin, isepamicin, astromycin, etimicin, neomycin, spectinomycin, tetracycline, paromomycin, doxycycline, minocycline, sulfacetamide sodium, norfloxacin, ofloxacin, enoxacin, ciprofloxacin, lomefloxacin, pefloxacin, rifloxacin, sparfloxacin, fleroxacin, moxifloxacin, rifampicin, metronidazole, tinidazole or cefoperazone; antiviral drugs, such as acyclovir, ganciclovir, valaciclovir or ribavirin; hormone drugs, such as dexamethasone phosphate, fluocinolone, beclomethasone, etc.; vitamin, such as vitamin B1, vitamin B2, vitamin B6, vitamin B12 or vitamin C, niacinamide or folic acid; anti-inflammatory drug, such as indometacin, ibuprofen, meloxicam, piroxicam, diclofenac sodium, paracetamol or nimesulide; antianaphylactic drug, such as chlorphenamine, diphenhydramine, tripeleminamine, etc.; immunoregulatory drug, such as  $\alpha$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi$ -,  $\psi$ -,  $\omega$ -,  $\alpha$ -,  $\beta$ -,  $\gamma$ -,  $\delta$ -,  $\epsilon$ -,  $\zeta$ -,  $\eta$ -,  $\theta$ -,  $\iota$ -,  $\kappa$ -,  $\lambda$ -,  $\mu$ -,  $\nu$ -,  $\xi$ -,  $\omicron$ -,  $\pi$ -,  $\rho$ -,  $\sigma$ -,  $\tau$ -,  $\upsilon$ -,  $\phi$ -,  $\chi</$



BHA, BHT, CDGA, tocopherol; isotonic regulator is boric acid, sodium dihydrogen phosphate, disodium hydrogen phosphate or glucose; thickening agent is Me cellulose, Et cellulose, etc.; cuticle lytic agent is menthol; tetrandrine is tetrandrine hydrochloride, tetrandrine sulfate, tetrandrine nitrate, tetrandrine phosphate, etc. Chlorhexidine, benzalkonium bromide, phenylhydrargyric nitrate, phenylhydrargyric acetate, chlorbutol, thiomersalate, mercuric oxycyanide, paraben, benzyl carbinol, sorbic acid, \*\*\*benzoic acid or domiphen are added in medical formulation while using non-antibiotic drugs. The ophthalmic preparation is used for treating chorioretinitis, ceratitis, anaphylactic ophthalmic disease, glaucoma and cataract, proliferative lesion of retinal vitreous body, etc.

IT 63-66-3, L-Methionine, biological studies 65-65-0,  
Benzoic acid, biological studies  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(ophthalmic comps. containing tetrandrine and synergistic drugs for  
treating eye diseases)  
RN 63-68-3 HCAPLUS  
CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



RN 65-85-0 HCAPLUS  
CN Benzoic acid (CA INDEX NAME)



L10 ANSWER 12 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2005:1195681 HCAPLUS Full-text  
DOCUMENT NUMBER: 143:439065  
TITLE: Anti-microbial composition comprising  
antimicrobial material, organic acid and  
emulsifier  
INVENTOR(S): Liang, Yu; Haiyan, Yang; Jianjun, Zhou; Thomas, Linda  
Valerie  
PATENT ASSIGNEE(S): Danisco A/S, Den.  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----		-----	-----	-----
WO 2005104878	A1	20051110	WO 2005-GB1700	20050504

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CN 101014255 A 20070808 CN 2005-80022796 20050504  
 PRIORITY APPLN. INFO.: GB 2004-10038 A 20040505  
 WO 2005-GB1700 W 20050504

AB An antimicrobial composition comprises (i) an antimicrobial material; (ii) an organic acid or salt thereof; and (iii) an emulsifier. Thus, an antimicrobial powder blend is prepared by combining an emulsifier synergistic with nisin with sodium diacetate such that the emulsifier is in the form of a powder.

IT 50-21-5, Lactic acid, biological studies  
 79-09-4, Propionic acid, biological studies  
 922-55-4

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (anti-microbial composition comprising antimicrobial material,  
 organic acid and emulsifier)


RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 79-09-4 HCAPLUS


CN Propanoic acid (CA INDEX NAME)



RN 922-55-4 HCAPLUS

CN L-Cysteine, S-[(2R)-2-amino-2-carboxyethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 50-21-5D, Lactic acid, monoglyceride esters

RL: FFD (Food or feed use); BIOL (Biological study); USES (Uses)  
 (emulsifier; anti-microbial composition comprising antimicrobial  
 material, organic acid and emulsifier)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 13 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1103175 HCAPLUS Full-text  
 DOCUMENT NUMBER: 143:392525  
 TITLE: Peptide-based body surface reagents for personal care  
 INVENTOR(S): Huang, Xueying; Wu, Ying; Wang, Hong; O'Brien, John P.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 57 pp., Cont.-in-part of U.S. Ser. No. 935,642.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050226839	A1	20051013	US 2005-74473	20050308
US 20050050656	A1	20050310	US 2004-935642	20040907
US 7220405	B2	20070522		
CA 2503838	A1	20050324	CA 2004-2503838	20040908
AU 2004269781	A1	20050512	AU 2004-269781	20040908
AU 2004269781	B2	20070628		
BR 2004006215	A	20050809	BR 2004-6215	20040908
EP 1663118	A2	20060607	EP 2004-788667	20040908
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
CN 1863501	A	20061115	CN 2004-80001202	20040908
JP 2007505132	T	20070308	JP 2006-526302	20040908
NO 2005001968	A	20050704	NO 2005-1968	20050422
MX 2005PA04820	A	20050920	MX 2005-PA4820	20050504
US 20060222609	A1	20061005	US 2006-389948	20060327
US 7285264	B2	20071023		
US 20070269394	A1	20071122	US 2007-778699	20070717
US 20080152600	A1	20080626	US 2008-971975	20080110
PRIORITY APPLN. INFO.:				
			US 2003-501498P	P 20030908
			US 2004-935642	A2 20040907
			US 2004-562645P	P 20040415
			WO 2004-US29514	W 20040908
			US 2005-74473	A2 20050308
			US 2006-389948	A3 20060327

AB Peptides have been identified that bind with high affinity to body surfaces, such as, hair, skin, nails, teeth, gums, corneal tissue, and oral cavity surfaces. Peptide-based body surface reagents formed by coupling a body surface binding peptide to a benefit agent are described. The peptide-based body surface reagents include peptide-based hair conditioners, hair colorants, skin conditioners, skin colorants, nail colorants, and oral care reagents. The peptide may be directly coupled to the active agent or the coupling may be via a spacer. Personal care compns. containing these peptide-based body surface reagents are also described. For example, a peptide-based hair

conditioner was prepared by covalently linking the hair-binding D21 peptide, given as SEQ ID NO 46, with behenyl alc. using carbodiimide coupling. Behenyl alc. 81.7 mg, and dicyclohexylcarbodiimide (DCC) 62.0 mg were dissolved in THF 2.0 mL in a 25 mL round-bottom flask. A solution containing 0.25 g of the 9-fluorenylmethyloxycarbonyl (Fmoc) N-terminal protected form of SEQ ID NO 46 in 2.0 mL dimethylormamide was added to the above mixture. Then, 50 µL of dimethylaminopyridine (DMAP) was added to the reaction mixture. With stirring, the reaction mixture was maintained at 40°. for 3 h, and then at room temperature overnight. Then the solvent was evaporated under vacuum at room temperature for 4 h. After this time, the mixture was dissolved in 25 mL of Et acetate, and the unreacted peptide was extracted 3 times with water using 10 mL of deionized water for each extraction. The Et acetate phase was isolated and the Et acetate was removed using a rotary evaporator. The resulting solid product was dissolved in a solvent consisting of 2.5 mL of THF and 2.5 mL of DMF, and 1.5 mL of piperidine was added to deblock the amino group of the D21 peptide. This mixture was stirred for 2 h at room temperature and then the solvents were removed by rotary evaporation under vacuum. The final product was characterized by LC/MS. The effectiveness of a composition containing a mixture of 0.25% of the peptide-based conditioner and 1.5% of Performix Lecithin in distilled water was demonstrated using dark brown hair swatches, showing better hair conditioning effects than Dow Corning 929 Cationic Emulsion conditioner.


IT 50-21-5, Lactic acid, biological studies  
847143-02-6  
RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)  
(peptide-based body surface reagents for personal care)  
RN 50-21-5 HCAPLUS  
CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)




RN 847143-02-6 HCAPLUS  
CN L-Methionine, L-leucyl-L-prolyl-L-alanyl-L-leucyl-L-histidyl-L-isoleucyl-L-glutamyl-L-arginyl-L-histidyl-L-prolyl-L-arginyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





L10 ANSWER 14 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:780841 HCAPLUS Full-text

DOCUMENT NUMBER: 141:291228

TITLE: Cloning, sequences and physical characterization of polypeptides of pathogenic bacteria and their use as antimicrobial targets

INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Thalakada, Rosanne; Arrowsmith, Cheryl; Ouyang, Hui; Domagala, Megan; Virag, Cristina; Beattie, Bryan; Mansoury, Kamran; Canadien, Veronica; Richards, Dawn; Ng, Ivy; Nethery, Kathleen; Houston, Simon; Buzadzija, Kristina; Tai, Matthew; Kanagarajah, Dhushy; Boora, Kamaljit; Alam, Muhammad Zahoor

PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 467 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004081206	A2	20040923	WO 2004-CA362	20040312
WO 2004081206	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20070072192	A1	20070329	US 2005-167924	20050627
PRIORITY APPLN. INFO.:				
			US 2003-453893P	P 20030312
			US 2003-453901P	P 20030312
			US 2003-454200P	P 20030312
			US 2003-454447P	P 20030313
			US 2003-454455P	P 20030313
			US 2003-454459P	P 20030313
			US 2003-454466P	P 20030313

US 2003-454474P	P	20030313
US 2003-454490P	P	20030313
US 2003-454497P	P	20030313
US 2003-454512P	P	20030313
US 2003-454521P	P	20030313
US 2003-454532P	P	20030313
US 2003-454769P	P	20030314
US 2003-454784P	P	20030314
US 2003-454811P	P	20030314
US 2003-454969P	P	20030314
US 2003-454973P	P	20030314
US 2003-454977P	P	20030314
US 2003-455007P	P	20030314
US 2003-455014P	P	20030314
US 2003-455019P	P	20030314
US 2003-455039P	P	20030314
US 2003-455090P	P	20030314
US 2003-455190P	P	20030317
US 2003-455230P	P	20030317
US 2003-455239P	P	20030317
US 2003-455314P	P	20030317
US 2003-455347P	P	20030317
US 2003-455358P	P	20030317
US 2003-455429P	P	20030317
US 2002-436551P	P	20021226
US 2002-436563P	P	20021226
US 2002-436587P	P	20021226
US 2002-436981P	P	20021230
US 2002-437007P	P	20021230
US 2002-437167P	P	20021230
US 2002-437274P	P	20021231
US 2002-437464P	P	20021231
US 2002-437532P	P	20021231
US 2002-437544P	P	20021231
US 2002-437552P	P	20021231
US 2002-437617P	P	20021231
US 2002-437618P	P	20021231
US 2002-437640P	P	20021231
WO 2003-CA19342	A2	20031219
WO 2004-CA362	A2	20040312

- AB The present invention relates to polypeptide targets for pathogenic bacteria. Reliable, high throughput methods are developed to identify, express, and purify a number of antimicrobial targets from *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Enterococcus faecalis*, *Hemophilus influenzae*, and *Pseudomonas aeruginosa*. The nucleic acid and amino acid sequences are provided for acetyl-CoA carboxylase, kinase, dihydrodipicolinate synthase, methylenetetrahydrofolate dehydrogenase, 2-amino-4-hydroxy-6-hydroxymethylidihydropteridine pyrophosphokinase, glycyl-tRNA synthetase, glycerol-3-phosphate dehydrogenase, protoporphyrinogen oxidase, phenylalanyl-tRNA synthetase, peptide chain release factor 2, CTP synthase, thymidylate synthase, tRNA (guanine-N1)-methyltransferase, tRNA (5-methylaminomethyl-2-thiouridylate)-methyltransferase, and tyrosyl-tRNA synthetase, and some other polypeptides. The invention also provides bioinformatic, biochem. and biophys. characteristics of those polypeptides, in particular characterization by mass spectrometry, NMR spectrometry, and x-ray crystallog.

IT 64-18-6, Formic acid, uses

RL: NUU (Other use, unclassified); USES (Uses)  
 (cryoprotectant; cloning, sequences and phys. characterization of polypeptides of pathogenic bacteria and their use as antimicrobial targets)

RN 64-18-6 HCAPLUS  
 CN Formic acid (CA INDEX NAME)



IT 760954-24-3 760954-71-6

RL: PRP (Properties)


(unclaimed sequence; cloning, sequences and phys. characterization of polypeptides of pathogenic bacteria and their use as antimicrobial targets)

RN 760954-24-3 HCAPLUS


CN L-Methionine, L-alanyl-L-arginyl-L-alanyl-L-valyl-L-threonyl-L-prolylglycyl-L-glutamyl-L-alanyl-L-valyl-L-valyl-L-phenylalanyl-L-tyrosyl-L- $\alpha$ -aspartylglycyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 760954-71-0 HCAPLUS

CN L-Methionine, L-alanyl-L-tyrosyl-L- $\alpha$ -glutamyl-L-leucyl-L-alanyl-L-glutamyl-L- $\alpha$ -glutamyl-L-leucylglycyl-L-valyl-L-tyrosyl- (9CI) (CA


INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L10 ANSWER 15 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:203593 HCAPLUS Full-text

DOCUMENT NUMBER: 140:234733

TITLE: Carboxylic acid microbicides for food, feed and water

INVENTOR(S): Schasteen, Charles S.; Wu, Jennifer; Buttin, Pierre; Hillebrand, Pieter; Scott, Fredrick R.; Vasquez-Anon, Mercedes

PATENT ASSIGNEE(S): Novus International, LLP, USA; Novus International, Inc.

SOURCE: PCT Int. Appl., 146 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019683	A2	20040311	WO 2003-US27323	20030829
WO 2004019683	A3	20040415		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,



TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,  
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  
 AU 2003268342 A1 20040319 AU 2003-268342 20030829  
 EP 1531672 A2 20050525 EP 2003-749300 20030829  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK  
 BR 2003013917 A 20050705 BR 2003-13917 20030829  
 IN 2005CN00275 A 20070330 IN 2005-CN275 20050225  
 MX 2005PA02307 A 20051018 MX 2005-PA2307 20050228  
 PRIORITY APPLN. INFO.:  
 US 2002-407050P P 20020830  
 US 2003-441384P P 20030121  
 US 2003-441584P P 20030121  
 US 2003-456673P P 20030321  
 US 2003-456732P P 20030321  
 US 2003-465549P P 20030425  
 WO 2003-US27323 W 20030829  
 OTHER SOURCE(S): MARPAT 140:234733  
 AB Antimicrobial compns. and combinations for food, feed and water comprise  
 carboxylic acids, preferably Alimet.  
 IT 50-21-5, Lactic acid, biological studies  
 64-18-6, Formic acid, biological studies  
 65-85-0, Benzoic acid, biological studies  
 79-09-4, Propionic acid, biological studies  
 107-32-6, Butyric acid, biological studies  
 110-17-8, Fumaric acid, biological studies  
 583-91-5, Alimet 666823-60-5, Alimet-lactic  
 acid mixture 666823-61-6, Alimet-formic  
 acid mixture 666823-62-7, Alimet-citric acid mixture  
 666823-63-8, Alimet-butyric acid mixture  
 666823-64-9, Alimet-propionic acid mixture  
 666823-69-3 666823-69-4, Alimet-fumaric  
 acid mixture 666823-70-7, Alimet-tartaric acid mixture  
 666823-71-8, Alimet-sorbic acid mixture 666823-72-9,  
 Alimet-malic acid mixture  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES  
 (Uses)  
 (carboxylic acid microbicides for food, feed and  
 water)  
 RN 50-21-5 HCAPLUS  
 CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)




RN 64-18-6 HCAPLUS  
 CN Formic acid (CA INDEX NAME)




RN 65-85-0 HCAPLUS  
 CN Benzoic acid (CA INDEX NAME)



RN 79-09-4 HCAPLUS  
 CN Propanoic acid (CA INDEX NAME)




RN 107-92-6 HCAPLUS  
 CN Butanoic acid (CA INDEX NAME)




RN 110-17-8 HCAPLUS  
 CN 2-Butenedioic acid (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 583-91-5 HCAPLUS  
 CN Butanoic acid, 2-hydroxy-4-(methylthio)- (CA INDEX NAME)



RN 666823-60-5 HCAPLUS  
 CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with 2-hydroxypropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5  
 CME C5 H10 O3 S



CM 2

CRN 50-21-5

CMF C3 H6 O3




RN 666823-61-6 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with formic acid (9CI)  
(CA INDEX NAME)

CM 1

CRN 583-91-5

CMF C5 H10 O3 S



CM 2

CRN 64-18-6

CMF C H2 O2




RN 666823-62-7 HCAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, mixt. with  
2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5


CMF C5 H10 O3 S



CM 2

CRN 77-92-9

CMF C6 H8 O7




RN 666823-63-8 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with butanoic acid (9CI)  
(CA INDEX NAME)

CM 1

CRN 583-91-5


CMF C5 H10 O3 S



CM 2

CRN 107-92-6

CMF C4 H8 O2




RN 666823-64-9 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with propanoic acid (9CI)  
(CA INDEX NAME)

CM 1

CRN 583-91-5


CMF C5 H10 O3 S



CM 2

CRN 79-09-4

CMF C3 H6 O2




RN 666823-68-3 HCAPLUS

CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with butanoic acid, formic acid and 2-hydroxypropanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5


CMF C5 H10 O3 S



CM 2

CRN 107-92-6

CMF C4 H8 O2



CM 3

CRN 64-18-6

CMF C H2 O2



CM 4

CRN 50-21-5

CMF C3 H6 O3




RN 666823-69-4 HCAPLUS

CN 2-Butenedioic acid (2E)-, mixt. with 2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5

CMF C5 H10 O3 S




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




RN 666823-70-7 HCAPLUS

CN Butanedioic acid, 2,3-dihydroxy- (2R,3R)-, mixt. with  
2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1

CRN 583-91-5

CMF C5 H10 O3 S




CM 2

CRN 87-69-4

CMF C4 H6 O6

Absolute stereochemistry.




RN 666823-71-8 HCAPLUS

CN 2,4-Hexadienoic acid, (2E,4E)-, mixt. with  
2-hydroxy-4-(methylthio)butanoic acid (9CI) (CA INDEX NAME)

CM 1


CRN 583-91-5  
CMF C5 H10 O3 S



CM 2

CRN 110-44-1  
CMF C6 H8 O2


Double bond geometry as shown.



RN 666823-72-9 HCAPLUS  
CN Butanoic acid, 2-hydroxy-4-(methylthio)-, mixt. with hydroxybutanedioic acid (9CI) (CA INDEX NAME)


CM 1

CRN 6915-15-7  
CMF C4 H6 O5



CM 2

CRN 583-91-5  
CMF C5 H10 O3 S



L10 ANSWER 16 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2003:925104 HCAPLUS [Full-text](#)  
DOCUMENT NUMBER: 140:145036  
TITLE: Nutritional, physiological, physicochemical and sensory stability of gamma irradiated Kimchi (Korean fermented vegetables)  
AUTHOR(S): Song, Hyun-Pa; Kim, Dong-Ho; Yook, Hong-Sun; Kim, Mee-Ree; Kim, Kyong-Soo; Byun, Myung-Woo

CORPORATE SOURCE: Department of Radiation Food Science and  
Biotechnology, Korea Atomic Energy Research Institute,  
Daejeon, 305-600, S. Korea

SOURCE: Radiation Physics and Chemistry (2004), 69(1), 85-90  
CODEN: RPCHDM; ISSN: 0969-806X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Effects of gamma irradiation on nutritional, physiol., physicochem. and sensory properties of the Korean lactic acid fermented vegetable, Kimchi, were investigated. The composition of amino acids and organic acids in Kimchi were not influenced by gamma irradiation less than 10 kGy. Angiotensin converting enzyme inhibitory, xanthin oxidase inhibitory, electron donating and antimicrobial activity of Kimchi extract were stable up to 10 kGy. There were no significant changes in pH and texture at less than 10 kGy. Color values were influenced at 10 kGy of gamma irradiation, and resulted in the increase of L\* and reduction of a\*-value. About 90% of panelists identified a sensory difference between non-irradiated and 10 kGy-irradiated sample, and Kimchi irradiated at 10 kGy had lower scores in acceptability than those of the control or irradiated at 2.5 and 5 kGy.

IT 50-21-5, Lacticacid, biological studies 63-68-3,  
L-Methionine, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(nutritional, physicochem., and sensory stability of  $\gamma$ -irradiated kimchi)

RN 50-21-5 HCAPLUS


CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 63-68-3 HCAPLUS

CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 17 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:261864 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:282444

TITLE: Cloning, purification and characterization of polypeptides from pathogenic bacteria involved in membrane biosynthesis, and drug screening and drug design applications

INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Houston, Simon; Kanagarajah, Dhushy; Li, Qin; Mansoury, Kamran;



McDonald, Merry-Lynn; Necakov, Sasha; Ng, Ivy; Pinder, Benjamin; Sheldrick, Bay; Vallee, Francois; Viola, Cristina; Wrezel, Olga  
 Affinium Pharmaceuticals, Inc., Can.  
 PATENT ASSIGNEE(S):  
 SOURCE: PCT Int. Appl., 312 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003027139	A2	20030403	WO 2002-CA1443	20020924
WO 2003027139	A3	20040219		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002328231	A1	20030407	AU 2002-328231	20020924
PRIORITY APPLN. INFO.:			US 2001-324449P	P 20010924
			US 2001-324504P	P 20010924
			US 2001-326269P	P 20011001
			US 2001-326887P	P 20011003
			US 2001-339560P	P 20011024
			US 2001-337471P	P 20011025
			US 2001-340000P	P 20011026
			US 2001-340002P	P 20011026
			US 2001-340027P	P 20011026
			US 2001-341767P	P 20011218
			US 2001-344307P	P 20011221
			US 2001-343946P	P 20011227
			WO 2002-CA1443	W 20020924
AB	The present invention relates to polypeptide targets for pathogenic bacteria. A number of antimicrobial target enzymes and proteins have been identified, expressed, and purified from <i>Staphylococcus aureus</i> , <i>Helicobacter pylori</i> , <i>Streptococcus pneumoniae</i> , and <i>Pseudomonas aeruginosa</i> . Cloning, the nucleotide sequences and the encoded amino acid sequences of genes <i>ftsZ</i> , <i>fabZ</i> , <i>acpS</i> , <i>murD</i> , <i>murC</i> , <i>fabH</i> , <i>tagD</i> , <i>obg</i> , and <i>fabG</i> from <i>S. aureus</i> , <i>H. pylori</i> , <i>S. pneumoniae</i> , and <i>P. aeruginosa</i> are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.			
IT	64-18-6, Formic acid, uses RL: NUU (Other use, unclassified); USES (Uses) (cryoprotectant; cloning, purification and characterization of polypeptides from pathogenic bacteria involved in membrane biosynthesis, and drug screening and drug design applications)			
RN	64-18-6 HCAPLUS			
CN	Formic acid (CA INDEX NAME)			



IT 504410-49-5

RL: PRP (Properties)


(unclaimed sequence; cloning, purification and characterization of polypeptides from pathogenic bacteria involved in membrane biosynthesis, and drug screening and drug design applications)

RN 504410-49-5 HCAPLUS


CN L-Methionine, L-tyrosyl-L-seryl-L-alanyl-L-alanyl-L-lysyl-L-leucylglycyl-L-isoleucyl-L-valyl-L-alanyl-L-leucyl-L-seryl-L-lysyl-L-seryl-L-isoleucyl-L-alanyl-L-leucyl-L- $\alpha$ -aspartyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





L10 ANSWER 18 OF 28 HCAPLUS COPYRIGHT 2008 ACS on SIN  
 ACCESSION NUMBER: 2003:242369 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 138:283309  
 TITLE: Cloning, purification and characterization of enzymes from pathogenic bacteria involved in protein processing and drug screening and drug design applications  
 INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Domagala, Megan; Kanagarajah, Dhushy; Li, Qin; Mansoury, Kamran; Necakov, Sasha; Nethery, Kathleen; Ng, Ivy; Pinder, Benjamin; Sheldrick, Bay; Vallee, Francois; Viola, Cristina; Wrezel, Olga; et al.  
 PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.  
 SOURCE: PCT Int. Appl., 273 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025005	A2	20030327	WO 2002-CA1426	20020920
WO 2003025005	A3	20040311		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,  
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002328222 A1 20030401 AU 2002-328222 20020920  
 US 2001-324135P P 20010921  
 US 2001-324139P P 20010921  
 US 2001-325333P P 20010927  
 US 2001-325836P P 20010928  
 US 2001-338235P P 20011025  
 US 2001-343758P P 20011025  
 US 2001-340531P P 20011026  
 US 2001-340945P P 20011030  
 US 2001-333281P P 20011106  
 US 2002-399926P P 20020731  
 WO 2002-CA1426 W 20020920

AB The present invention relates to polypeptide targets for pathogenic bacteria. A number of antimicrobial target enzymes have been identified, expressed, and purified from *Staphylococcus aureus*, *Helicobacter pylori*, *Streptococcus pneumoniae*, and *Escherichia coli*. Cloning, the nucleotide sequences and the encoded amino acid sequences of genes *clpL*, *cysM*, *pepP*, *kdsA*, *seca*, *trmD*, *ilvE*, *aroB*, and *glyA* from *S. aureus*, *H. pylori*, *S. pneumoniae*, and *E. coli* are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.

IT 64-18-6, Formic acid, uses  
 RL: NUU (Other use, unclassified); USES (Uses)  
 (cryoprotectant; cloning, purification and characterization of enzymes from pathogenic bacteria involved in protein processing, and drug screening and drug design applications)



RN 64-18-6 HCAPLUS  
 CN Formic acid (CA INDEX NAME)

○—CH—OH

IT 503586-98-9 503587-32-4  
 RL: PRP (Properties)  
 (unclaimed sequence; cloning, purification and characterization of enzymes from pathogenic bacteria involved in protein processing and drug screening and drug design applications)

RN 503586-98-9 HCAPLUS  
 CN L-Methionine, L-prolyl-L-glutamyl-L-isoleucyl-L-leucyl-L-threonyl-L-leucyl-L-leucyl-L-leucyl-L-glutamyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 503587-32-4 HCAPLUS

CN L-Methionine, L-lysyl-L-glutamyl-L-valyl-L-leucyl-L-phenylalanyl-L-cysteinyl-L-prolyl-L-lysyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L10 ANSWER 19 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:242368 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:282426

TITLE: Cloning, purification and characterization of polypeptides from pathogenic bacteria involved in nucleic acid processing and drug screening and drug design applications

INVENTOR(S): Edwards, Aled; Dharamsi, Akil; Vedadi, Masoud; Alam, Muhammad Zahoor; Arrowsmith, Cheryl; Awrey, Donald; Beattie, Bryan; Canadien, Veronica; Cox, Brian; Domagala, Megan; Houston, Simon; Li, Qin; Nethery, Kathleen; Ng, Ivy; Ouyang, Hui; Pinder, Benjamin; Sheldrick, Bay; Viola, Cristina; Wrezel, Olga

PATENT ASSIGNEE(S): Affinium Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 298 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 16

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003025004	A2	20030327	WO 2002-CA1411	20020918
WO 2003025004	A3	20040304		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002328215	A1	20030401	AU 2002-328215	20020918
PRIORITY APPLN. INFO.:				
			US 2001-323040P	P 20010918
			US 2001-325307P	P 20010927
			US 2001-325421P	P 20010927
			US 2001-325891P	P 20010928
			US 2001-326337P	P 20011001
			US 2001-326774P	P 20011003
			US 2001-327193P	P 20011004

US 2001-340922P	P	20011030
US 2001-338709P	P	20011105
US 2001-333269P	P	20011106
US 2001-341679P	P	20011218
WO 2002-CA1411	W	20020918


- AB The present invention relates to polypeptide targets for pathogenic bacteria. A number of antimicrobial target enzymes and proteins have been identified, expressed, and purified from *Staphylococcus aureus*, *Helicobacter pylori*, *Streptococcus pneumoniae*, and *Pseudomonas aeruginosa*. Cloning, the nucleotide sequences and the encoded amino acid sequences of genes *nrdE*, *pyrH*, *pnpA*, *ung*, *rho*, *pnp*, *pyrE*, *lig*, *dnaN*, *nrdF*, and *nrdE* from *S. aureus*, *H. pylori*, *S. pneumoniae*, and *P. aeruginosa* are disclosed. The invention also provides biochem. and biophys. characteristics of those polypeptides. The polypeptides are characterized by using mass spectrometry, NMR, x-ray crystallog., and bioinformatics anal. The polypeptides of the invention can be used for drug screening, drug design, in diagnostic assays and in pharmacol. applications.
- IT 64-18-6, Formic acid, uses  
 RL: NUU (Other use, unclassified); USES (Uses)  
 (cryoprotectant; cloning, purification, sequences, and characterization of polypeptides from pathogenic bacteria involved in nucleic acid processing, and drug screening and drug design applications)
- RN 64-18-6 HCAPLUS
- CN Formic acid (CA INDEX NAME)



- IT 503608-18-2  
 RL: PRP (Properties)  
 (unclaimed sequence; cloning, purification and characterization of polypeptides from pathogenic bacteria involved in nucleic acid processing and drug screening and drug design applications)
- RN 503608-18-2 HCAPLUS
- CN L-Methionine, L-leucyl-L-prolyl-L-isoleucyl-L-valyl-L-valyl-L-cysteinyl-L-asparaginyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



SMe

L10 ANSWER 20 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:154270 HCAPLUS Full-text  
 DOCUMENT NUMBER: 138:198572  
 TITLE: Antimicrobial cationic peptides and  
 formulations thereof  
 INVENTOR(S): Krieger, Timothy J.; McNicol, Patricia J.; Fraser,  
 Janet R.  
 PATENT ASSIGNEE(S): Micrologix Biotech Inc., Can.  
 SOURCE: PCT Int. Appl., 90 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003015809	A2	20030227	WO 2002-US26525	20020821
WO 2003015809	A3	20040318		
WO 2003015809	A9	20040422		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GO, GW, ML, MR, NE, SN, TD, TG				
US 20030171281	A1	20030911	US 2002-225087	20020820
US 6835536	B2	20041228		
CA 2456477	A1	20030227	CA 2002-2456477	20020821
AU 2002324752	A1	20030303	AU 2002-324752	20020821
AU 2002324752	B2	20080703		
EP 1469876	A2	20041027	EP 2002-759416	20020821
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005504769	T	20050217	JP 2003-520767	20020821
US 20050049182	A1	20050303	US 2004-865687	20040610
PRIORITY APPLN. INFO.:				
			US 2001-314232P	P 20010821
			US 2002-225087	A 20020820
			WO 2002-US26525	W 20020821
AB Comps. and methods for making and using therapeutic formulations of antimicrobial cationic peptides are provided. The antimicrobial cationic peptide formulations may be used, for example, in the treatment of microorganism-caused infections, which infections may be systemic, such as a septicemia, or may be localized, such as in acne or an implanted or indwelling medical device.				
IT 50-51-5, Lactic acid, uses 65-85-0, Benzoic acid, uses 110-17-8, Fumaric acid, uses				
RL: MOA (Modifier or additive use); USES (Uses)				



10/652,745

(antimicrobial cationic peptides and formulations thereof)

RN 50-21-5 HCAPLUS

CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 65-85-0 HCAPLUS


CN Benzoic acid (CA INDEX NAME)



RN 110-17-8 HCAPLUS

CN 2-Butenedioic acid (2E)- (CA INDEX NAME)

Double bond geometry as shown.



IT 204245-19-2 204245-20-5 204245-29-4

RL: PRP (Properties)


(unclaimed sequence; antimicrobial cationic peptides and formulations thereof)

RN 204245-19-2 HCAPLUS


CN L-Methionine, L-isoleucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 204245-20-5 HCAPLUS

CN L-Methionine, L-isoleucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-L-isoleucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A








RN 204245-29-4 HCAPLUS

CN L-Methionine, L-isoleucyl-L-leucyl-L-lysyl-L-lysyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L-arginyl-L-arginyl-L-lysyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.





L10 ANSWER 21 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2002:429415 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 136:385273  
 TITLE: Highly acidic metalated organic acid as a food additive  
 INVENTOR(S): Kemp, Maurice Clarence; Lalum, Robert Blaine; Lewis, David E.; Carpenter, Robert H.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 655,131.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020068114	A1	20020606	US 2001-766546	20010119
US 6572908	B2	20030603		
US 6881424	B1	20050419	US 2000-655131	20000905
CA 2435233	A1	20020725	CA 2002-2435233	20020110
WO 2002056712	A2	20020725	WO 2002-US782	20020110
WO 2002056712	A3	20030227		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002245249 A1 20020730 AU 2002-245249 20020110  
 AU 2002245249 B2 20061214  
 EP 1353571 A2 20031022 EP 2002-713395 20020110  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004517629 T 20040617 JP 2002-557228 20020110  
 CN 1625347 A 20050608 CN 2002-805550 20020110  
 CN 100382725 C 20080423  
 US 20030161926 A1 20030828 US 2003-368229 20030218  
 US 6808730 B2 20041026  
 US 20050215638 A1 20050929 US 2005-108325 20050418  
 PRIORITY APPLN. INFO.: US 2000-655131 A2 20000905  
 US 2001-766546 A 20010119  
 WO 2002-US782 W 20020110

AB A highly acidic metalated organic acid composition ("HAMO") is prepared and used as a food additive. The HAMO is used to reduce biol. contaminants, and thus preserve, a nutriment. The HAMO is being absorbed in, or adsorbed on, a nutriment material to give a prepared nutriment. Thus, the HAMO can be prepared by mixing at least one regenerating acid, at least one metal base, and at least one organic acid, wherein the amount of the regenerating acid is in excess of the equivalent amount of the metal base.


IT 50-21-5, Lactic acid, biological studies  
 63-68-3, Methionine, biological studies 64-18-6, Formic acid, biological studies 79-09-4, Propionic acid, biological studies  
 RL: FFD (Food or feed use); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)  
 (acidic metalated organic acid as a food additive)

RN 50-21-5 HCAPLUS  
 CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)


Absolute stereochemistry.



RN 64-18-6 HCAPLUS  
 CN Formic acid (CA INDEX NAME)



RN 79-09-4 HCAPLUS  
CN Propanoic acid (CA INDEX NAME)



L10 ANSWER 22 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2002:184846 HCAPLUS Full-text  
DOCUMENT NUMBER: 136:231605  
TITLE: Highly acidic metalated organic acid manufacture as food biocide  
INVENTOR(S): Kemp, Maurice Clarence; Lalum, Robert Blaine; Lewis, David E.; Carpenter, Robert H.  
PATENT ASSIGNEE(S): Mionix Corporation, USA  
SOURCE: PCT Int. Appl., 55 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019846	A2	20020314	WO 2001-US41954	20010830
WO 2002019846	A3	20020620		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 6881424	B1	20050419	US 2000-655131	20000905
CA 2420670	A1	20020314	CA 2001-2420670	20010830
AU 2001093234	A	20020322	AU 2001-93234	20010830
EP 1322187	A2	20030702	EP 2001-973680	20010830
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004508026	T	20040318	JP 2002-524338	20010830
AU 2001293234	B2	20060727	AU 2001-293234	20010830
US 20050215638	A1	20050929	US 2005-108325	20050418
PRIORITY APPLN. INFO.:			US 2000-655131	A 20000905
			WO 2001-US41954	W 20010830

AB A highly acidic metalated organic acid composition and its preparation are described. The acidic composition can be prepared by mixing a monovalent or polyvalent cation and an organic acid in the presence of a strong oxyacid, wherein the resultant acidic composition is less corrosive to a ferrous metal than a solution of a mineral acid having the same acidic pH value as that of the acidic composition, and wherein the acid composition is more biocidal than a mixture of the organic acid and metal salt of the organic acid when the mixture has the same acid normality value as that of the acidic composition. The acidic composition can be prepared by mixing at least one regenerating acid, at least one metal base, and at least one organic acid, wherein the


amount of the regenerating acid is in excess of the equivalent amount of the metal base.

- IT 50-21-5, Lactic acid, reactions  
 53-68-3, L-Methionine, reactions 64-18-6, Formic acid, reactions 79-09-4, Propionic acid, reactions 107-92-6, Butyric acid, reactions  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (highly acidic metalated organic acid manufacture as food biocide)  
 RN 50-21-5 HCAPLUS  
 CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)



- RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)


Absolute stereochemistry.




- RN 64-18-6 HCAPLUS  
 CN Formic acid (CA INDEX NAME)



- RN 79-09-4 HCAPLUS  
 CN Propanoic acid (CA INDEX NAME)



- RN 107-92-6 HCAPLUS  
 CN Butanoic acid (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2001:874340 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 136:10931  
 TITLE: Cosmetics containing plant extracts and other active agents  
 INVENTOR(S): Yoshida, Yatsuka  
 PATENT ASSIGNEE(S): Musashino Meneki Kenkyusho, Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001335422	A	20011204	JP 2000-195287	20000526
JP 2005255668	A	20050922	JP 2005-2656	20050107

PRIORITY APPLN. INFO.: JP 2000-195287 A3 20000526  
 AB This invention relates to cosmetic comps. comprising (1) *Bidens pilosa* exts. and (2) circulation promoters, antimicrobials, anti-inflammatories, moisturizers, skin-lightening agents, UV ray absorbers, and/or UV ray scattering agents. A skin cream contained *Bidens pilosa* exts. 1, Mg ascorbyl phosphate 1, licorice exts. 0.1, 1,3-butylene glycol 5, glycerin 3, squalane 10, jojoba oil 5, paraffin oils 10, stearic acid 5, beeswax 2, polyoxyethylene cetyl ether 3, cetanol 2, glycerin monostearate 2, olive oil 5, propylparaben 0.1, and distilled water q.s. to 100 %.  
 IT 63-68-3, Methionine, biological studies 65-85-0D,  
 Benzoic acid, salts  
 RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)  
 (cosmetics containing plant exts. and other skin-active agents)  
 RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



RN 65-85-0 HCAPLUS  
 CN Benzoic acid (CA INDEX NAME)



L10 ANSWER 24 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2001:489201 HCAPLUS [Full-text](#)  
 DOCUMENT NUMBER: 135:81832  
 TITLE: Hair compositions containing zinc pyrithione and piroctone olamine for the treatment of dandruff




INVENTOR(S): Dascalu, Avi; Oron, Yoram  
 PATENT ASSIGNEE(S): Pharmaskin Ltd., Israel  
 SOURCE: PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001047481	A1	20010705	WO 2000-IL849	20001220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			IL 1999-133760	A 19991228
AB A composition for the treatment of seborrheic dermatitis of scalp (dandruff) comprises a mixture of bisabolol, 1 of its derivs. or c zinc pyrithione and piroctone olamine and/or their derivs. The composition advantageously comprises 0.001-20% zinc pyrithione and 0.02-20% piroctone olamine. The bisabolol is preferably part of a chamomile extract. The composition may comprise also a compound selected from keratolytic agents, antiproliferatives, antifungals, antimicrobials, germicides, anti-irritancy agents anti-inflammatory agents, sterols, hair nourishment agents, lipid derivs., refrigerants, herbal exts., vasodilators, nitric oxide donors and hair stimulating and/or hair invigorating agents. The present invention relates also to the treatment of humans and animals against seborrheic dermatitis and to a method for the treatment. Thus, a shampoo formulation contained zinc pyrithione 1.50, piroctone olamine 0.60, bisabolol 0.25, magnesium aluminum silicate 1.20, tetrasodium pyrophosphate 0.06, water 51.39, sodium laureth sulfate 40.00, and myristamide DEA 5.00%, citric acid and preservative and fragrance qs.				
IT 50-21-5, Lactic acid, biological studies 63-68-3, L-Methionine, biological studies RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (hair comps. containing zinc pyrithione and piroctone olamine for treatment of dandruff)				
RN 50-21-5 HCAPLUS				
CN Propanoic acid, 2-hydroxy- (CA INDEX NAME)				



RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 25 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:736197 HCAPLUS Full-text  
 DOCUMENT NUMBER: 133:277176  
 TITLE: Regulated expression systems and plasmid vectors for use in lactic acid bacteria hosts  
 INVENTOR(S): Madsen, Soeren Michael; Vrang, Astrid; Arnau, Jose; Ravn, Peter; Johnsen, Mads Groenvald; Israelsen, Hans  
 PATENT ASSIGNEE(S): Biotechnologisk Institut, Den.  
 SOURCE: U.S., 45 pp., Cont.-in-part of U.S. Ser. No. 711,434, abandoned.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6133023	A	20001017	US 1997-981601	19971229
WO 9810079	A1	19980312	WO 1997-DK341	19970822
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW RW: GH, KE, LS, MM, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 757106	B2	20030206	AU 2001-65568	20010830
PRIORITY APPLN. INFO.:			US 1996-711434	B2 19960906
			WO 1997-DK341	W 19970822
			AU 1997-39382	A3 19970822

AB Expression vectors that replicate in lactic acid bacteria and that carry regulatable expression cassettes that can be used to drive expression of a gene of interest are described. The expression cassettes may use known regulatory elements in novel combinations to give distinct regulatory or induction properties to the cassette. Cells containing such a regulatable or inducible gene expression system are useful as food or feed starter cultures or as strains for the production of gene products such as pharmaceutically or immunol. active compds. including oligo- or polypeptides derived from a Mycobacterium species including M. tuberculosis. An inducible pH regulated promoter of Lactococcus lactus was cloned using a promoter probe vector with a lacZ reporter gene. A minimal promoter was identified by deletion anal. and the promoter used to develop a range of expression vectors based on prior art replicons supporting plasmid replication in lactic acid bacteria. The use of the promoter to drive expression of the gene for Staphylococcus aureus RNase is demonstrated.

IT 300380-18-3

RL: PRP (Properties)


(Unclaimed; regulated expression systems and plasmid vectors for use in lactic acid bacteria hosts)

RN 300380-78-3 HCAPLUS


CN L-Methionine, L-seryl-L-phenylalanyl-L-arginyl-L- $\alpha$ -glutamyl-L-leucyl-L- $\alpha$ -glutamyl-L-isoleucyl-L-cysteinyl-L-arginyl-L-isoleucyl-L-prolylglycyl-L-asparaginy-L-phenylalanyl-L- $\alpha$ -glutamyl-L-arginyl-L-isoleucyl-L-phenylalanyl-L-leucyl- (9CI) (CA INDEX NAME)





Absolute stereochemistry.

PAGE 1-A



PAGE 2-A





REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 26 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:335239 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 132:339384

TITLE: Ionic silver complex

INVENTOR(S): Newman, Ira Jay; Washburn, David

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 24 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027390	A1	20000518	WO 1999-US26223	19991105
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1128824	A1	20010905	EP 1999-971711	19991105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 9915174	A	20011106	BR 1999-15174	19991105
JP 2002529411	T	20020910	JP 2000-580619	19991105
NZ 512267	A	20031128	NZ 1999-512267	19991105
AU 776212	B2	20040902	AU 2000-14701	19991105
US 20020025344	A1	20020228	US 2001-796242	20010228
MX 2001PA05900	A	20020311	MX 2001-PA5900	20010611
US 20020150628	A1	20021017	US 2002-175260	20020618
US 20030147970	A1	20030807	US 2003-383345	20030307
US 6838095	B2	20050104		
US 20050118281	A1	20050602	US 2005-28840	20050104
PRIORITY APPLN. INFO.:			US 1998-107710P	P 19981109
			US 1999-435158	B1 19991105
			WO 1999-US26223	W 19991105
			US 2001-796242	B1 20010228
			US 2002-175260	B1 20020618
			US 2003-383345	A1 20030307
AB	The invention relates to a substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, and a substantially water-soluble complexing agent. A solution was prepared containing citric acid, K citrate, and silver oxide.			
IT	50-21-5, Lactic acid, biological studies 63-68-3, L-Methionine, biological studies RL: MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ionic silver complex)			
RN	50-21-5 HCAPLUS			
CN	Propanoic acid, 2-hydroxy- (CA INDEX NAME)			



RN 63-68-3 HCAPLUS  
 CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 27 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1991:623438 HCAPLUS Full-text

DOCUMENT NUMBER: 115:223438

ORIGINAL REFERENCE NO.: 115:37871a,37874a

TITLE: Method of evaluating the physiological activities and structural characteristics of medicinal substances using lipid films on crystal oscillators

INVENTOR(S): Okahata, Yoshio; Yomemori, Kazuyuki; Fujita, Shinsuke

PATENT ASSIGNEE(S): Sogo Pharmaceutical Co., Ltd., Japan

SOURCE: Eur. Pat. Appl., 19 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 420683	A2	19910403	EP 1990-310663	19900928
EP 420683	A3	19920115		
R: CH, DE, FR, GB, IT, LI, NL, SE				
JP 03115858	A	19910516	JP 1989-251858	19890929
PRIORITY APPLN. INFO.:			JP 1989-251858	A 19890929

AB A method of evaluating the physiol. and structural characteristics of medicinal substances uses crystal oscillators having lipid films to determine correlations of (A) physiol. activity factors and/or structural characteristics of the medicinals with (B) change in frequency, adsorption amts., lipid film-water partition coeffs., or other lipid film interaction characteristic. The antimicrobial activity of long-chain fatty acids against Gram-pos. bacteria showed good correlation with the partition coefficient using a lipid film of polystyrene sulfonic acid dialkylammonium salt. The partition coefficient of 70 substances in this film correlated well with Draize scores as an indication of toxicity.

IT 65-85-0, Benzoic acid, biological studies

13073-35-3, Ethionine

RL: PRP (Properties)

(interaction of, with polyion complex lipid film on crystal oscillator, toxicity correlation with)

RN 65-85-0 HCAPLUS


CN Benzoic acid (CA INDEX NAME)



RN 13073-35-3 HCAPLUS

CN L-Homocysteine, S-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 28 OF 28 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:532820 HCAPLUS Full-text

DOCUMENT NUMBER: 113:132820

ORIGINAL REFERENCE NO.: 113:22599a,22602a

TITLE: Preparation of diaminopropionic acid-containing peptides as antimicrobials

INVENTOR(S): Andruszkiewicz, Ryszard; Chmara, Henryk; Milewski, Slawomir; Borowski, Edward

PATENT ASSIGNEE(S): Politechnika Gdanska, Pol.

SOURCE: Pol., 10 pp. Abstracted and indexed from the unexamined application.

CODEN: POXXA7

DOCUMENT TYPE:

Patent

LANGUAGE:

Polish

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PL 145455	B1	19880930	PL 1984-258604	19841016
PRIORITY APPLN. INFO.:			PL 1984-258604	19841016


AB The title compds.  $\text{RCOCH}(\text{NH}_2)\text{CH}_2\text{NHCOCH:CHCO}_2\text{R}_1$  (I; R = residue of monoaminomonocarboxylic amino acid;  $\text{R}_1 = \text{C1-4 alkyl, C3-5 isoalkyl, cyclohexyl}$ ) are prepared. An alkyl ester of fumaric acid is activated and reacted with N2-tert-butoxycarbonyl-L-2,3- diaminopropanoic acid in a polar organic solvent or its mixture with water. The resulting N2-tert-butoxycarbonyl, N3-4-alkoxyfumaroyl-L-2,3-diaminopropanoic acid is converted to an active ester which is used for acylation of a monoaminomonocarboxylic amino acid. The resulting N-protected dipeptide is deprotected and isolated as a salt or free acid. I have high antifungal activity (e.g., against *Candida albicans*), and antibacterial activity. Thus, (E)-MeO2CCH:CHCO2Q (Q = succinimido) was reacted with N2-tert-butoxycarbonyl-L-2,3- diaminopropanoic acid in an aqueous MeOH solution at 0° to give (E)-MeO2CCH:CHCONHCH2CH(NHBOC)CO2H. The latter was reacted with N-hydroxysuccinimide and dicyclohexylcarbodiimide for 1 h at 0° and 24 h at room temperature. After removing dicyclohexyl urea the filtrate was concentrated to give (E)-MeO2CCH:CHCONHCH2CH(NHBOC)Q1. The latter was reacted with L-methionine to give (E)-MeO2CCH:CHCONHCH2CH(NHBOC)-Met-OH, which was contacted with trifluoroacetic acid to give (E)-MeO2CCH:CHCONHCH2CH(NH2)-Met-OH.

IT 122593-27-5P 125515-79-9P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of, as antimicrobial)

RN 122593-27-5 HCAPLUS

CN L-Methionine, N-[N-[(1,1-dimethylethoxy)carbonyl]-3-[(4-methoxy-1,4-dioxo-2-butenyl)amino]-L-alanyl]-, (E)- (9CI) (CA INDEX NAME)



RN 125515-79-9 HCAPLUS


CN L-Methionine, N-[3-[(4-methoxy-1,4-dioxo-2-butenyl)amino]-L-alanyl]-, (E)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 108233-36-9

CMF C13 H21 N3 O6 S

Absolute stereochemistry.  
Double bond geometry as shown.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



IT 63-68-3, L-Methionine, reactions


RL: RCT (Reactant); RACT (Reactant or reagent)

(reaction of, in preparation of antimicrobial peptides)

RN 63-68-3 HCAPLUS

CN L-Methionine (CA INDEX NAME)

Absolute stereochemistry.





## SEARCH HISTORY

=&gt; d his ful

(FILE 'HOME' ENTERED AT 15:23:07 ON 16 DEC 2008)

FILE 'REGISTRY' ENTERED AT 15:23:19 ON 16 DEC 2008

L1 STR  
 L2 50 SEA SSS SAM L1  
 L3 STR L1  
 L4 50 SEA SSS SAM L3  
 L5 31381 SEA SSS FUL L3

FILE 'HCAPLUS' ENTERED AT 15:30:40 ON 16 DEC 2008

L6 86246 SEA ABB=ON L5  
 L7 558 SEA ABB=ON L6 AND ?ANTIMICROB?  
 L8 117 SEA ABB=ON L7 AND (FOOD OR WATER)

FILE 'REGISTRY' ENTERED AT 15:32:09 ON 16 DEC 2008

L9 6 SEA ABB=ON (FORMIC ACID OR BUTYRIC ACID OR FUMARIC ACID OR  
 LACTIC ACID OR BENZOIC ACID OR PROPIONIC ACID)/CN

FILE 'HCAPLUS' ENTERED AT 15:32:31 ON 16 DEC 2008

L10 28 SEA ABB=ON L8 AND (L9 OR FORMIC ACID OR BUTYRIC ACID OR  
 FUMARIC ACID OR LACTIC ACID OR BENZOIC ACID OR PROPIONIC ACID)  
 E SCHASTEEN CHARLES S/AU  
 L11 45 SEA ABB=ON ("SCHASTEEN C S"/AU OR "SCHASTEEN CHARLES"/AU OR  
 "SCHASTEEN CHARLES S"/AU OR "SCHASTEEN CHARLES STEVEN"/AU)  
 E WU JENNIFER/AU  
 L12 34 SEA ABB=ON ("WU JENN SHENG"/AU OR "WU JENN YU"/AU OR "WU  
 JENNIFER"/AU OR "WU JENNIFER D"/AU OR "WU JENNIFER DONGLAN"/AU)  
 E BUTTIN PIERRE/AU  
 L13 6 SEA ABB=ON ("BUTTIN P"/AU OR "BUTTIN PIERRE"/AU)  
 E HILLEBRAND PIETER/AU  
 L14 2 SEA ABB=ON ("HILLEBRAND PETER"/AU OR "HILLEBRAND PIETER"/AU)  
 E SCOTT FREDRICK R/AU  
 L15 1 SEA ABB=ON "SCOTT FREDRICK R"/AU  
 E VASQUEZ ANON MERCEDES/AU  
 L16 1 SEA ABB=ON "VASQUEZ ANON MERCEDES"/AU

FILE 'REGISTRY' ENTERED AT 15:36:32 ON 16 DEC 2008

E ANON MERCEDES/CN

FILE 'HCAPLUS' ENTERED AT 15:36:32 ON 16 DEC 2008

E ANON MERCEDES/AU  
 L17 1 SEA ABB=ON L11 AND L12 AND L13 AND L14 AND L15 AND L16  
 SELECT RN L17 1-1

FILE 'REGISTRY' ENTERED AT 15:37:46 ON 16 DEC 2008

L18 31 SEA ABB=ON (10043-35-3/BI OR 107-92-6/BI OR 110-15-6/BI OR  
 110-17-8/BI OR 110-44-1/BI OR 110-94-1/BI OR 124-04-9/BI OR  
 50-21-5/BI OR 583-91-5/BI OR 64-18-6/BI OR 64-19-7/BI OR  
 65-85-0/BI OR 666823-60-5/BI OR 666823-61-6/BI OR 666823-62-7/B  
 I OR 666823-63-8/BI OR 666823-64-9/BI OR 666823-65-0/BI OR  
 666823-66-1/BI OR 666823-67-2/BI OR 666823-68-3/BI OR 666823-69  
 -4/BI OR 666823-70-7/BI OR 666823-71-8/BI OR 666823-72-9/BI OR  
 6915-15-7/BI OR 77-92-9/BI OR 79-09-4/BI OR 79-14-1/BI OR  
 87-69-4/BI OR 90-64-2/BI)

FILE 'HCAPLUS' ENTERED AT 15:37:51 ON 16 DEC 2008  
L19 1 SEA ABB=ON L17 AND L18  
SAV L8 KAN745L8/A

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 15 DEC 2008 HIGHEST RN 1084993-68-9  
DICTIONARY FILE UPDATES: 15 DEC 2008 HIGHEST RN 1084993-68-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Dec 2008 VOL 149 ISS 25  
FILE LAST UPDATED: 15 Dec 2008 (20081215/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.